SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)
Clinical trials for SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN) explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN) trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer drug TAK-500 tested in 61 patients – study halted early
Disease control TerminatedThis early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…
Matched conditions: SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental cancer drug TAK-186 tested in patients with advanced tumors
Disease control TerminatedThis study tested a new drug called TAK-186 in 95 adults with advanced or metastatic cancers of the head and neck, lung, or colon that could not be removed by surgery. The main goal was to check for side effects and find the best dose. The study was stopped early, so results are …
Matched conditions: SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC